Market Access and Medical Affairs with Proven Impact on Hospitals and Patients

We support pharmaceutical companies in Market Access and Medical Affairs by linking hospital process optimisation with patient experience and professional engagement. Our approach is designed to respond directly to payer and hospital priorities — improving adherence, coordination and rational use of resources — while creating legitimacy with healthcare professionals.

For Market Access, the service strengthens positioning and negotiation by demonstrating measurable improvements in clinical outcomes (60%+), efficiency (65%) and care coordination (61%). These impacts consistently exceed international benchmarks, reinforcing the value of innovation beyond the product and providing a credible basis for access and financing discussions.

For Medical Affairs, the methodology enables structured patient involvement in clinical research, from protocol design to follow-up, capturing emotional, social and informational dimensions often overlooked in conventional trials. By integrating patient and professional perspectives, the projects generate reliable data that complements traditional endpoints and supports broader adoption of therapies in real clinical practice.

The result is a service that delivers:

• Operational change in hospitals without major structural investments.

• Evidence of clinical and efficiency benefits aligned with system priorities.

• Cultural transformation through stronger professional–patient relationships.

• Enhanced trial relevance by embedding patient participation into study design and implementation.

In short, we provide pharmaceutical partners with a proven way to negotiate access, support clinical adoption, and involve patients authentically in trials — all through practical, hospital-based interventions.